Commerce Bank Takes $39,000 Position in Mural Oncology plc (NASDAQ:MURA)

Commerce Bank acquired a new stake in Mural Oncology plc (NASDAQ:MURA) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 12,423 shares of the company’s stock, valued at approximately $39,000. Commerce Bank owned approximately 0.07% of Mural Oncology as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. BBR Partners LLC bought a new stake in shares of Mural Oncology in the 2nd quarter worth about $31,000. Rhumbline Advisers bought a new stake in shares of Mural Oncology in the 2nd quarter worth about $34,000. Canada Pension Plan Investment Board bought a new stake in shares of Mural Oncology in the 2nd quarter worth about $70,000. Dimensional Fund Advisors LP bought a new stake in shares of Mural Oncology in the 2nd quarter worth about $71,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Mural Oncology in the 2nd quarter worth about $84,000. Institutional investors and hedge funds own 80.21% of the company’s stock.

Mural Oncology Stock Up 2.8 %

Shares of NASDAQ:MURA opened at $4.04 on Thursday. Mural Oncology plc has a 12 month low of $2.88 and a 12 month high of $6.25. The company’s 50-day moving average price is $3.44 and its two-hundred day moving average price is $3.36. The firm has a market cap of $68.76 million and a P/E ratio of -0.43.

Insiders Place Their Bets

In other Mural Oncology news, CFO Adam D. Cutler sold 7,421 shares of the stock in a transaction dated Thursday, October 31st. The shares were sold at an average price of $3.41, for a total transaction of $25,305.61. Following the sale, the chief financial officer now owns 71,438 shares of the company’s stock, valued at $243,603.58. This represents a 9.41 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

MURA has been the topic of several analyst reports. Raymond James initiated coverage on shares of Mural Oncology in a report on Friday, October 4th. They issued a “strong-buy” rating and a $18.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Mural Oncology in a report on Monday, November 11th.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.